Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Swiss National Bank boosted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 1.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 188,400 ...

10x Genomics, Inc., a life science technology company ... as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Charles Schwab Investment Management Inc. lessened its stake in 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 17.2% in the ...

10x Genomics, Inc. (NASDAQ ... Customers can now run million cell experiments with a single chip and in a single run. They can also do so at a price point of $0.01 per cell with our GEM-X Flex ...

Whitaker, Chief Legal Officer of 10x Genomics. "We are pleased with this resolution on ATAC as we continue to defend the asserted Brenner patents on appeal." The company's litigation against Parse ...

Explore 10x Genomics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for TXG. Life Science Company 10x Genomics Struggles With Profitability, Analyst Says ...

The Genomics Core houses a 10X Genomics Chromium iX which has the capacity to prepare ... most genomic data - including bulk and single cell RNAseq, ATAC-seq, Cut&Run, ChIP-seq, and Cut&Tag. We are ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ — 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.